Imagine being told your newborn twins may never walk or hold up their heads. This devastating reality is what former Little Mix singer Jesy Nelson is facing after her twins, Ocean and Story, were diagnosed with Type 1 Spinal Muscular Atrophy (SMA). But here's where it gets even more heart-wrenching: this rare genetic condition progressively weakens muscles, and while treatments exist, there's no cure.
In a candid Instagram video, Jesy shared the heartbreaking news, emphasizing the urgency of starting treatment and hoping for the best. But what exactly is SMA, and how does it impact lives? Let’s break it down in a way that’s easy to understand, even if you’re hearing about it for the first time.
What is SMA?
Spinal Muscular Atrophy (SMA) is a rare genetic disorder that causes muscle weakness and deterioration over time. According to the NHS, it’s caused by a faulty gene called SMN1, which is inherited from both parents. Here’s the kicker: most parents who carry this gene don’t even know it, and they don’t have SMA themselves.
And this is the part most people miss: SMA isn’t a one-size-fits-all condition. It’s categorized into four main types based on when symptoms appear and how severely they affect movement:
- Type 1: Diagnosed in babies under six months, often the most severe form.
- Type 2: Affects babies and toddlers aged six to 17 months.
- Type 3: Seen in children and teenagers from 18 months to 17 years.
- Type 4: Occurs in adults aged 18 and over, typically milder.
The Genetics Behind SMA: A Family Affair
Here’s where it gets a bit controversial. SMA is recessive, meaning both parents must carry the faulty gene for a child to inherit the condition. If both parents are carriers:
- There’s a 25% chance their child will have SMA.
- A 50% chance the child will be a carrier but not affected.
- A 25% chance the child will neither have SMA nor carry the gene.
This raises questions: Should all couples undergo genetic testing before starting a family? Is it ethical to screen embryos for SMA? Let’s discuss this in the comments—what’s your take?
How SMA Impacts Lives
The NHS highlights that SMA affects everyone differently. Early onset, like in Jesy’s twins, often means a more severe prognosis. While some individuals may live full lives with manageable symptoms, others face significant challenges, including reduced life expectancy.
Diagnosis and Screening: A Game-Changer
SMA can be diagnosed through a simple blood test if suspected. Prenatal tests like chorionic villus sampling (CVS) or amniocentesis can also detect it during pregnancy. Excitingly, Scotland is set to become the first part of the UK to introduce routine newborn screening for SMA in 2026, funded by the Scottish Government and Novartis. This two-year pilot could save countless families from late diagnoses.
Countries like France, Germany, and Sweden already screen newborns nationwide. Why isn’t this standard everywhere? Is it a matter of resources, awareness, or prioritization? Share your thoughts below.
Treatments: Hope on the Horizon
While there’s no cure, treatments like Nusinersen (Spinraza), Risdiplam (Evrysdi), and the groundbreaking Zolgensma (priced at £1.79 million per dose!) target the genetic cause of SMA. However, not everyone qualifies for these treatments, and access remains a significant issue.
Take five-year-old Edward Willis-Hall, for example, who received Zolgensma through Good Morning Britain’s coverage. His story highlights both the promise and the challenges of these life-changing therapies.
Final Thoughts: A Call to Action
Jesy Nelson’s story sheds light on the realities of SMA, but it also sparks important conversations. Should genetic screening be mandatory? How can we make expensive treatments more accessible? And what more can we do to support families like Jesy’s?
This isn’t just a medical issue—it’s a societal one. Let’s keep the dialogue going. Share your opinions, experiences, or questions in the comments. Together, we can raise awareness and drive change for those affected by SMA.
